Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Sangamo Biosciences ( (SGMO) ) has shared an update.
Pfizer has terminated its collaboration with Sangamo Therapeutics regarding the development and commercialization of the gene therapy giroctocogene fitelparvovec for hemophilia A. As a result, the collaboration agreement will end on April 21, 2025, halting any royalties and milestone payments from Pfizer to Sangamo. Sangamo will regain an exclusive, sublicensable license from Pfizer to continue the product’s development and will seek a new partner for regulatory approval and commercialization.
More about Sangamo Biosciences
Sangamo Therapeutics, Inc. operates in the biotechnology industry, focusing on developing gene therapy products. The company’s primary product candidate is giroctocogene fitelparvovec, a gene therapy for hemophilia A. Sangamo’s market focus is on innovative genetic therapies, utilizing technologies such as the adeno-associated virus (AAV) delivery system.
YTD Price Performance: 371.45%
Average Trading Volume: 8,604,907
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $534.1M
Learn more about SGMO stock on TipRanks’ Stock Analysis page.
